25 XP   0   0   10

Evoke Pharma Inc
Buy, Hold or Sell?

Let's analyse Evoke Pharma Inc together

PenkeI guess you are interested in Evoke Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Evoke Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Evoke Pharma Inc

I send you an email if I find something interesting about Evoke Pharma Inc.

Quick analysis of Evoke Pharma Inc (30 sec.)










What can you expect buying and holding a share of Evoke Pharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.30
Expected worth in 1 year
$-1.09
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-0.79
Return On Investment
-167.8%

For what price can you sell your share?

Current Price per Share
$0.47
Expected price per share
$0 - $0.57
How sure are you?
50%

1. Valuation of Evoke Pharma Inc (5 min.)




Live pricePrice per Share (EOD)

$0.47

Intrinsic Value Per Share

$-6.05 - $-4.11

Total Value Per Share

$-6.36 - $-4.41

2. Growth of Evoke Pharma Inc (5 min.)




Is Evoke Pharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$2.5m$4.6m-$4.8m-2,476.1%

How much money is Evoke Pharma Inc making?

Current yearPrevious yearGrowGrow %
Making money-$2m-$2m$39.6k2.0%
Net Profit Margin-173.7%-365.9%--

How much money comes from the company's main activities?

3. Financial Health of Evoke Pharma Inc (5 min.)




What can you expect buying and holding a share of Evoke Pharma Inc? (5 min.)

Welcome investor! Evoke Pharma Inc's management wants to use your money to grow the business. In return you get a share of Evoke Pharma Inc.

What can you expect buying and holding a share of Evoke Pharma Inc?

First you should know what it really means to hold a share of Evoke Pharma Inc. And how you can make/lose money.

Speculation

The Price per Share of Evoke Pharma Inc is $0.4685. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Evoke Pharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Evoke Pharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.30. Based on the TTM, the Book Value Change Per Share is $-0.20 per quarter. Based on the YOY, the Book Value Change Per Share is $0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Evoke Pharma Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.23-50.0%-0.22-46.7%-0.24-51.8%-0.26-56.0%-0.30-63.2%
Usd Book Value Change Per Share-0.20-42.9%-0.20-41.9%0.023.3%-0.04-8.3%-0.07-15.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.20-42.9%-0.20-41.9%0.023.3%-0.04-8.3%-0.07-15.0%
Usd Price Per Share1.05-1.50-2.07-1.79-2.99-
Price to Earnings Ratio-1.12--1.72--2.17--1.79--2.81-
Price-to-Total Gains Ratio-5.22--7.63--5.65--8.24-9.38-
Price to Book Ratio-3.45-4.18-3.60--2.81-1.71-
Price-to-Total Gains Ratio-5.22--7.63--5.65--8.24-9.38-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.4685
Number of shares2134
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.20-0.04
Usd Total Gains Per Share-0.20-0.04
Gains per Quarter (2134 shares)-419.37-83.13
Gains per Year (2134 shares)-1,677.48-332.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1677-16870-333-343
20-3355-33640-665-676
30-5032-50410-998-1009
40-6710-67180-1330-1342
50-8387-83950-1663-1675
60-10065-100720-1995-2008
70-11742-117490-2328-2341
80-13420-134260-2660-2674
90-15097-151030-2993-3007
100-16775-167800-3325-3340

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.045.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%3.017.00.015.0%10.030.00.025.0%13.032.00.028.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.045.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%3.017.00.015.0%10.030.00.025.0%13.032.00.028.9%

Fundamentals of Evoke Pharma Inc

About Evoke Pharma Inc

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Fundamental data was last updated by Penke on 2024-04-11 07:20:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Evoke Pharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Evoke Pharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Evoke Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -118.6% means that $-1.19 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Evoke Pharma Inc:

  • The MRQ is -118.6%. The company is making a huge loss. -2
  • The TTM is -173.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-118.6%TTM-173.7%+55.1%
TTM-173.7%YOY-365.9%+192.2%
TTM-173.7%5Y-826.8%+653.0%
5Y-826.8%10Y-413.4%-413.4%
1.1.2. Return on Assets

Shows how efficient Evoke Pharma Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Evoke Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -28.1% Return on Assets means that Evoke Pharma Inc generated $-0.28 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Evoke Pharma Inc:

  • The MRQ is -28.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -23.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.1%TTM-23.7%-4.4%
TTM-23.7%YOY-17.3%-6.4%
TTM-23.7%5Y-26.0%+2.2%
5Y-26.0%10Y-27.2%+1.2%
1.1.3. Return on Equity

Shows how efficient Evoke Pharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Evoke Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.0% Return on Equity means Evoke Pharma Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Evoke Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-115.6%+115.6%
TTM-115.6%YOY-55.7%-59.9%
TTM-115.6%5Y-53.4%-62.2%
5Y-53.4%10Y-61.9%+8.5%

1.2. Operating Efficiency of Evoke Pharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Evoke Pharma Inc is operating .

  • Measures how much profit Evoke Pharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Evoke Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Evoke Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-131.6%+131.6%
TTM-131.6%YOY-348.1%+216.5%
TTM-131.6%5Y-796.2%+664.6%
5Y-796.2%10Y-398.1%-398.1%
1.2.2. Operating Ratio

Measures how efficient Evoke Pharma Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 2.13 means that the operating costs are $2.13 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Evoke Pharma Inc:

  • The MRQ is 2.126. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.597. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.126TTM2.597-0.471
TTM2.597YOY4.481-1.883
TTM2.5975Y8.668-6.071
5Y8.66810Y4.334+4.334

1.3. Liquidity of Evoke Pharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Evoke Pharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.25 means the company has $2.25 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Evoke Pharma Inc:

  • The MRQ is 2.249. The company is able to pay all its short-term debts. +1
  • The TTM is 3.992. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.249TTM3.992-1.743
TTM3.992YOY7.861-3.869
TTM3.9925Y4.547-0.555
5Y4.54710Y5.238-0.691
1.3.2. Quick Ratio

Measures if Evoke Pharma Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Evoke Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.78 means the company can pay off $1.78 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Evoke Pharma Inc:

  • The MRQ is 1.783. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.540. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.783TTM3.540-1.757
TTM3.540YOY7.365-3.825
TTM3.5405Y4.229-0.689
5Y4.22910Y4.936-0.707

1.4. Solvency of Evoke Pharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Evoke Pharma Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Evoke Pharma Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 1.36 means that Evoke Pharma Inc assets are financed with 136.5% credit (debt) and the remaining percentage (100% - 136.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Evoke Pharma Inc:

  • The MRQ is 1.365. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.051. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.365TTM1.051+0.314
TTM1.051YOY0.632+0.419
TTM1.0515Y0.718+0.333
5Y0.71810Y0.606+0.112
1.4.2. Debt to Equity Ratio

Measures if Evoke Pharma Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Evoke Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Evoke Pharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.850-4.850
TTM4.850YOY1.999+2.851
TTM4.8505Y1.815+3.035
5Y1.81510Y1.590+0.226

2. Market Valuation of Evoke Pharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Evoke Pharma Inc generates.

  • Above 15 is considered overpriced but always compare Evoke Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -1.12 means the investor is paying $-1.12 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Evoke Pharma Inc:

  • The EOD is -0.500. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.120. Based on the earnings, the company is expensive. -2
  • The TTM is -1.719. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.500MRQ-1.120+0.620
MRQ-1.120TTM-1.719+0.599
TTM-1.719YOY-2.169+0.450
TTM-1.7195Y-1.786+0.067
5Y-1.78610Y-2.807+1.021
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Evoke Pharma Inc:

  • The EOD is -0.898. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.013. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.547. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.898MRQ-2.013+1.115
MRQ-2.013TTM-2.547+0.535
TTM-2.547YOY-2.879+0.332
TTM-2.5475Y-2.413-0.134
5Y-2.41310Y-3.167+0.754
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Evoke Pharma Inc is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Evoke Pharma Inc:

  • The EOD is -1.540. Based on the equity, the company is expensive. -2
  • The MRQ is -3.452. Based on the equity, the company is expensive. -2
  • The TTM is 4.179. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD-1.540MRQ-3.452+1.912
MRQ-3.452TTM4.179-7.631
TTM4.179YOY3.604+0.575
TTM4.1795Y-2.811+6.990
5Y-2.81110Y1.710-4.521
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Evoke Pharma Inc.

3.1. Institutions holding Evoke Pharma Inc

Institutions are holding 29.977% of the shares of Evoke Pharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc0.352102985100
2023-12-31Geode Capital Management, LLC0.319202706500
2023-12-31Tower Research Capital LLC0.0760.0001644665311.2722
2023-12-31UBS Group AG0.0344029142077.6468
2023-12-31BlackRock Inc0.01740147300
2023-12-31Morgan Stanley - Brokerage Accounts0.004403753750
2023-12-31Goss Wealth Management LLC0.0025020800
2023-12-31Royal Bank of Canada0.000302800
2023-12-31Wells Fargo & Co0.000302628.3333
2023-12-31CWM, LLC duplicate0.000201600
2023-12-31Concord Wealth Partners000-31-100
Total 0.80680.000168402+1206+1.8%

3.2. Funds holding Evoke Pharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.352102985100
2024-02-29Fidelity Extended Market Index0.215601828000
2024-02-29Fidelity Nasdaq Composite Index0.05290448600
2024-02-29Fidelity Series Total Market Index0.03490295800
2023-12-31Northern Trust Extended Eq Market Idx0.02380202100
2023-12-31NT Ext Equity Mkt Idx Fd - L0.02380202100
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.01430121500
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0115097620.2053
2024-02-29Spartan Total Market Index Pool E0.01084700
2023-12-31SSgA U.S. Extended Market Index Class I0.0077065000
2024-03-31State St US Extended Mkt Indx NL Cl C0.0077065000
2024-02-29Fidelity Total Market Index0.0058049400
2023-12-31NT US Market Cap Idx Fd - L0.0028023900
2023-12-31Northern Trust Wilshire 50000.0028023900
2023-12-31SSgA U.S. Total Market Index Strategy0.00220187-4-2.0942
2023-12-31BNYM Mellon SL Market Completion UC10.00130108-2-1.8182
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.000503900
Total 0.7697065261-40.0%

3.3. Insider Transactions

Insiders are holding 9.645% of the shares of Evoke Pharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2020-12-14David A GonyerSELL239542.94

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Evoke Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.201-0.197-2%0.016-1388%-0.039-81%-0.070-65%
Book Value Per Share---0.304-0.023-92%0.553-155%0.333-191%0.520-159%
Current Ratio--2.2493.992-44%7.861-71%4.547-51%5.238-57%
Debt To Asset Ratio--1.3651.051+30%0.632+116%0.718+90%0.606+125%
Debt To Equity Ratio---4.850-100%1.999-100%1.815-100%1.590-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.234-0.219-7%-0.243+3%-0.262+12%-0.296+26%
Free Cash Flow Per Share---0.130-0.147+13%-0.195+49%-0.214+64%-0.244+87%
Free Cash Flow To Equity Per Share---0.145-0.154+6%0.236-161%0.040-462%-0.012-92%
Gross Profit Margin--1.0001.0000%1.0000%1.052-5%1.367-27%
Intrinsic Value_10Y_max---4.110--------
Intrinsic Value_10Y_min---6.051--------
Intrinsic Value_1Y_max---0.866--------
Intrinsic Value_1Y_min---0.919--------
Intrinsic Value_3Y_max---2.255--------
Intrinsic Value_3Y_min---2.507--------
Intrinsic Value_5Y_max---3.228--------
Intrinsic Value_5Y_min---3.803--------
Market Cap3971849.300-124%8904233.34012674946.835-30%17559643.250-49%15213539.267-41%25384313.538-65%
Net Profit Margin---1.186-1.737+47%-3.659+209%-8.268+597%-4.134+249%
Operating Margin----1.3160%-3.4810%-7.9620%-3.9810%
Operating Ratio--2.1262.597-18%4.481-53%8.668-75%4.334-51%
Pb Ratio-1.540+55%-3.4524.179-183%3.604-196%-2.811-19%1.710-302%
Pe Ratio-0.500+55%-1.120-1.719+53%-2.169+94%-1.786+59%-2.807+151%
Price Per Share0.469-124%1.0501.495-30%2.071-49%1.795-41%2.994-65%
Price To Free Cash Flow Ratio-0.898+55%-2.013-2.547+27%-2.879+43%-2.413+20%-3.167+57%
Price To Total Gains Ratio-2.328+55%-5.220-7.635+46%-5.653+8%-8.243+58%9.376-156%
Quick Ratio--1.7833.540-50%7.365-76%4.229-58%4.936-64%
Return On Assets---0.281-0.237-16%-0.173-38%-0.260-8%-0.272-3%
Return On Equity----1.1560%-0.5570%-0.5340%-0.6190%
Total Gains Per Share---0.201-0.197-2%0.016-1388%-0.039-81%-0.070-65%
Usd Book Value---2579537.000-197196.750-92%4685642.000-155%2822219.400-191%4407360.775-159%
Usd Book Value Change Per Share---0.201-0.197-2%0.016-1388%-0.039-81%-0.070-65%
Usd Book Value Per Share---0.304-0.023-92%0.553-155%0.333-191%0.520-159%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.234-0.219-7%-0.243+3%-0.262+12%-0.296+26%
Usd Free Cash Flow---1106104.000-1246244.250+13%-1648996.750+49%-1816300.400+64%-2068153.125+87%
Usd Free Cash Flow Per Share---0.130-0.147+13%-0.195+49%-0.214+64%-0.244+87%
Usd Free Cash Flow To Equity Per Share---0.145-0.154+6%0.236-161%0.040-462%-0.012-92%
Usd Market Cap3971849.300-124%8904233.34012674946.835-30%17559643.250-49%15213539.267-41%25384313.538-65%
Usd Price Per Share0.469-124%1.0501.495-30%2.071-49%1.795-41%2.994-65%
Usd Profit---1987401.000-2000885.000+1%-2040530.750+3%-2249197.050+13%-2522430.175+27%
Usd Revenue--1675994.0001295157.500+29%627161.250+167%466518.550+259%233259.275+619%
Usd Total Gains Per Share---0.201-0.197-2%0.016-1388%-0.039-81%-0.070-65%
 EOD+2 -6MRQTTM+13 -18YOY+13 -185Y+13 -1910Y+12 -20

4.2. Fundamental Score

Let's check the fundamental score of Evoke Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.500
Price to Book Ratio (EOD)Between0-1-1.540
Net Profit Margin (MRQ)Greater than0-1.186
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.783
Current Ratio (MRQ)Greater than12.249
Debt to Asset Ratio (MRQ)Less than11.365
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.281
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Evoke Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.498
Total1/1 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Debt  -4,7151,593-3,1211,168-1,9541,002-9511,212261



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets7,069
Total Liabilities9,648
Total Stockholder Equity-2,580
 As reported
Total Liabilities 9,648
Total Stockholder Equity+ -2,580
Total Assets = 7,069

Assets

Total Assets7,069
Total Current Assets6,827
Long-term Assets242
Total Current Assets
Cash And Cash Equivalents 4,739
Net Receivables 673
Inventory 482
Other Current Assets 933
Total Current Assets  (as reported)6,827
Total Current Assets  (calculated)6,827
+/-0
Long-term Assets
Long-term Assets Other 242
Long-term Assets  (as reported)242
Long-term Assets  (calculated)242
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities3,036
Long-term Liabilities6,612
Total Stockholder Equity-2,580
Total Current Liabilities
Accounts payable 1,712
Other Current Liabilities 1,324
Total Current Liabilities  (as reported)3,036
Total Current Liabilities  (calculated)3,036
+/-0
Long-term Liabilities
Long term Debt 5,000
Long-term Liabilities  (as reported)6,612
Long-term Liabilities  (calculated)5,000
+/- 1,612
Total Stockholder Equity
Common Stock0
Retained Earnings -123,439
Other Stockholders Equity 120,860
Total Stockholder Equity (as reported)-2,580
Total Stockholder Equity (calculated)-2,580
+/-0
Other
Capital Stock0
Cash and Short Term Investments 4,739
Common Stock Shares Outstanding 3,343
Liabilities and Stockholders Equity 7,069
Net Debt 261
Net Invested Capital 2,420
Net Working Capital 3,791
Short Long Term Debt Total 5,000



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-31
> Total Assets 
905
0
0
0
116
1,680
1,793
23,738
24,986
22,567
17,023
13,391
15,302
12,621
10,608
11,683
9,532
6,872
4,636
10,813
9,294
14,838
13,156
10,759
7,942
5,585
6,626
7,018
5,660
4,363
7,631
7,327
6,396
4,638
8,267
6,751
9,434
19,296
17,557
11,650
10,573
9,026
14,404
13,411
11,851
10,039
8,980
7,853
7,069
7,0697,8538,98010,03911,85113,41114,4049,02610,57311,65017,55719,2969,4346,7518,2674,6386,3967,3277,6314,3635,6607,0186,6265,5857,94210,75913,15614,8389,29410,8134,6366,8729,53211,68310,60812,62115,30213,39117,02322,56724,98623,7381,7931,680116000905
   > Total Current Assets 
0
0
0
0
116
1,670
1,050
23,738
24,431
22,012
16,935
13,308
15,249
12,574
10,608
11,675
9,524
6,872
4,636
10,813
9,283
14,827
13,144
10,748
7,930
5,585
6,626
7,007
5,648
4,260
7,561
7,292
6,246
4,533
8,196
6,715
9,281
19,176
17,472
11,601
10,561
9,026
14,404
13,257
11,722
9,948
8,927
7,840
6,827
6,8277,8408,9279,94811,72213,25714,4049,02610,56111,60117,47219,1769,2816,7158,1964,5336,2467,2927,5614,2605,6487,0076,6265,5857,93010,74813,14414,8279,28310,8134,6366,8729,52411,67510,60812,57415,24913,30816,93522,01224,43123,7381,0501,6701160000
       Cash And Cash Equivalents 
866
0
0
0
116
1,670
1,050
23,738
24,197
21,835
16,046
12,177
14,156
11,692
9,883
10,739
8,691
6,100
4,129
10,380
9,007
14,655
12,556
10,413
7,679
5,406
6,531
6,568
5,319
4,029
7,440
6,505
5,664
4,133
7,990
6,281
8,069
18,186
16,721
11,142
9,145
7,701
13,451
12,350
9,844
8,213
7,006
5,965
4,739
4,7395,9657,0068,2139,84412,35013,4517,7019,14511,14216,72118,1868,0696,2817,9904,1335,6646,5057,4404,0295,3196,5686,5315,4067,67910,41312,55614,6559,00710,3804,1296,1008,69110,7399,88311,69214,15612,17716,04621,83524,19723,7381,0501,670116000866
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
336
23
128
198
222
295
419
366
675
625
687
1,024
1,234
673
6731,2341,0246876256753664192952221981282333600000000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
86
236
236
234
225
186
279
268
220
289
365
514
505
482
4825055143652892202682791862252342362368600000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
11
743
0
556
556
88
83
53
47
0
8
8
8
0
0
12
12
12
12
12
12
0
12
12
103
70
35
150
105
71
36
153
120
85
49
12
0
0
154
129
91
53
13
242
2421353911291540012498512015336711051503570103121201212121212120088804753838855655607431100000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
103
70
35
139
105
71
36
142
120
85
49
12
0
0
154
129
91
53
13
0
0135391129154001249851201423671105139357010300000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
743
0
555
556
88
83
53
47
0
8
8
0
0
0
11
11
12
11
12
0
0
12
12
0
0
0
12
0
0
0
153,256
0
0
0
0
0
0
0
0
0
0
0
0
000000000000153,256000120001212001211121111000880475383885565550743000000
> Total Liabilities 
335
0
0
0
19,775
21,830
3,729
4,515
3,803
4,116
1,854
1,700
6,113
6,188
6,296
6,375
6,067
6,115
6,163
6,110
5,507
6,904
6,386
8,700
5,776
1,196
1,266
1,611
1,634
1,287
1,285
2,154
2,015
1,716
8,641
8,674
12,649
11,485
11,592
6,877
7,018
7,092
7,213
7,878
7,767
7,913
8,441
8,727
9,648
9,6488,7278,4417,9137,7677,8787,2137,0927,0186,87711,59211,48512,6498,6748,6411,7162,0152,1541,2851,2871,6341,6111,2661,1965,7768,7006,3866,9045,5076,1106,1636,1156,0676,3756,2966,1886,1131,7001,8544,1163,8034,5153,72921,83019,775000335
   > Total Current Liabilities 
335
0
0
0
570
668
1,488
2,637
2,285
2,944
1,837
1,685
1,872
2,500
3,194
2,006
1,834
2,434
6,163
1,012
1,412
1,136
1,879
2,649
2,075
1,196
1,266
1,611
1,634
1,287
1,285
2,154
2,015
1,716
6,641
6,621
7,536
6,249
6,231
1,390
1,406
1,357
1,353
1,878
1,655
1,678
2,081
2,240
3,036
3,0362,2402,0811,6781,6551,8781,3531,3571,4061,3906,2316,2497,5366,6216,6411,7162,0152,1541,2851,2871,6341,6111,2661,1962,0752,6491,8791,1361,4121,0126,1632,4341,8342,0063,1942,5001,8721,6851,8372,9442,2852,6371,488668570000335
       Short-term Debt 
0
0
0
0
0
0
701
1,070
1,443
1,443
0
0
150
713
1,252
0
146
709
4,400
0
146
0
0
0
0
0
0
0
0
103
70
35
139
105
175
140
246
120
85
49
12
0
0
140
129
91
53
13
0
01353911291400012498512024614017510513935701030000000014604,40070914601,252713150001,4431,4431,070701000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
127
0
0
0
146
0
0
0
0
0
0
0
0
0
0
0
0
103
0
0
0
0
104
104
104
0
0
0
0
0
0
0
0
0
0
0
0
0000000000001041041040000103000000000000146000127000000000000
       Accounts payable 
89
0
0
0
97
0
601
1,567
842
1,501
1,837
1,685
1,709
1,778
1,937
2,003
1,688
1,726
1,763
1,012
1,412
1,136
1,879
2,649
2,075
1,196
1,266
1,611
1,634
1,184
1,215
2,119
1,877
1,611
605
766
1,274
691
519
531
874
944
824
1,021
934
1,186
1,415
1,397
1,712
1,7121,3971,4151,1869341,0218249448745315196911,2747666051,6111,8772,1191,2151,1841,6341,6111,2661,1962,0752,6491,8791,1361,4121,0121,7631,7261,6882,0031,9371,7781,7091,6851,8371,5018421,56760109700089
       Other Current Liabilities 
246
0
0
0
570
668
786
1,567
842
1,501
1,837
1,685
1,721
1,787
1,943
2,006
1,688
1,726
1,763
1,012
1,266
1,136
1,879
2,649
2,075
1,196
1,266
1,611
1,634
1,184
1,215
2,119
1,877
1,611
5,861
5,715
6,016
9
6
811
519
1,357
529
717
591
1,586
2,028
2,227
1,324
1,3242,2272,0281,5865917175291,357519811696,0165,7155,8611,6111,8772,1191,2151,1841,6341,6111,2661,1962,0752,6491,8791,1361,2661,0121,7631,7261,6882,0061,9431,7871,7211,6851,8371,5018421,567786668570000246
   > Long-term Liabilities 
0
0
0
0
19,205
21,162
2,241
1,878
1,518
1,172
17
15
4,241
3,688
3,102
4,369
4,233
3,681
0
5,098
4,095
5,769
4,507
6,051
3,701
3,701
0
0
0
0
0
0
0
0
2,000
2,053
5,113
5,236
5,360
5,486
5,612
5,736
5,860
6,000
6,112
6,236
6,360
6,486
6,612
6,6126,4866,3606,2366,1126,0005,8605,7365,6125,4865,3605,2365,1132,0532,000000000003,7013,7016,0514,5075,7694,0955,09803,6814,2334,3693,1023,6884,24115171,1721,5181,8782,24121,16219,2050000
       Long term Debt Total 
0
0
0
0
0
0
0
1,878
1,511
1,157
0
0
4,241
3,688
3,102
4,369
4,233
3,681
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,000
2,000
5,000
5,000
5,000
0
0
0
0
0
0
0
0
0
0
00000000005,0005,0005,0002,0002,00000000000000000003,6814,2334,3693,1023,6884,241001,1571,5111,8780000000
       Other Liabilities 
0
0
0
0
0
0
0
0
7
16
17
15
0
0
0
0
0
0
0
5,098
4,095
5,768
4,507
6,050
3,701
0
0
0
0
0
0
0
0
0
0
53
113
236
360
486
612
736
860
986
1,112
1,236
1,360
0
0
001,3601,2361,1129868607366124863602361135300000000003,7016,0504,5075,7684,0955,0980000000151716700000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
7
16
17
15
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000151716700000000
> Total Stockholder Equity
570
0
0
0
-19,659
-20,150
-1,936
19,223
21,183
18,451
15,169
11,691
9,189
6,433
4,312
5,308
3,465
757
-1,527
4,703
3,788
7,934
6,770
2,060
2,166
4,389
5,360
5,408
4,025
3,075
6,346
5,173
4,381
2,922
-374
-1,923
-3,215
7,811
5,966
4,773
3,555
1,934
7,191
5,533
4,085
2,126
538
-874
-2,580
-2,580-8745382,1264,0855,5337,1911,9343,5554,7735,9667,811-3,215-1,923-3742,9224,3815,1736,3463,0754,0255,4085,3604,3892,1662,0606,7707,9343,7884,703-1,5277573,4655,3084,3126,4339,18911,69115,16918,45121,18319,223-1,936-20,150-19,659000570
   Common Stock
0
0
0
0
0
1
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
0
0
0
0
0
0
0
0000000333333332222222222222111111111111110100000
   Retained Earnings Total Equity0000000000-103,781-101,491-98,885-96,617-94,488-87,521-85,730-84,312-82,684-80,570-78,605-76,844-75,325-73,021-71,039-70,730-65,487-63,861-58,809-57,282-54,257-51,286-48,061-45,436-42,701-39,460-35,939-33,019-29,194-25,647-22,691-21,0750000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000000000000000-23,738,0530000000
   Capital Surplus 
0
0
0
0
0
0
0
40,297
43,874
44,097
44,363
44,709
45,127
45,893
47,012
50,743
51,525
52,042
52,729
61,984
62,596
71,793
72,256
72,788
73,203
77,409
80,683
82,250
82,628
83,644
89,028
89,483
90,108
90,440
94,112
94,691
95,668
109,299
109,744
0
0
0
0
0
0
0
0
0
0
0000000000109,744109,29995,66894,69194,11290,44090,10889,48389,02883,64482,62882,25080,68377,40973,20372,78872,25671,79362,59661,98452,72952,04251,52550,74347,01245,89345,12744,70944,36344,09743,87440,2970000000
   Treasury Stock0000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
196
198
18,653
40,297
43,874
44,097
44,363
44,709
45,127
45,893
47,012
50,743
51,525
52,042
52,729
61,984
62,596
71,793
72,256
72,788
73,203
77,409
80,683
82,250
82,628
83,644
89,028
89,483
90,108
90,440
94,112
94,691
95,668
109,299
109,744
110,521
110,975
111,527
119,021
119,376
119,731
120,016
120,296
120,578
120,860
120,860120,578120,296120,016119,731119,376119,021111,527110,975110,521109,744109,29995,66894,69194,11290,44090,10889,48389,02883,64482,62882,25080,68377,40973,20372,78872,25671,79362,59661,98452,72952,04251,52550,74347,01245,89345,12744,70944,36344,09743,87440,29718,6531981960000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue5,181
Cost of Revenue-202
Gross Profit4,9794,979
 
Operating Income (+$)
Gross Profit4,979
Operating Expense-12,410
Operating Income-7,431-7,431
 
Operating Expense (+$)
Research Development182
Selling General Administrative11,034
Selling And Marketing Expenses0
Operating Expense12,41011,216
 
Net Interest Income (+$)
Interest Income145
Interest Expense-500
Other Finance Cost-0
Net Interest Income-355
 
Pretax Income (+$)
Operating Income-7,431
Net Interest Income-355
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-7,792-7,069
EBIT - interestExpense = -500
-7,792
-7,292
Interest Expense500
Earnings Before Interest and Taxes (EBIT)0-7,292
Earnings Before Interest and Taxes (EBITDA)-7,431
 
After tax Income (+$)
Income Before Tax-7,792
Tax Provision-0
Net Income From Continuing Ops-7,608-7,792
Net Income-7,792
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses12,612
Total Other Income/Expenses Net-361355
 

Technical Analysis of Evoke Pharma Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Evoke Pharma Inc. The general trend of Evoke Pharma Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Evoke Pharma Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Evoke Pharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.5577 < 0.56 < 0.57.

The bearish price targets are: .

Tweet this
Evoke Pharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Evoke Pharma Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Evoke Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Evoke Pharma Inc.

Evoke Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartEvoke Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Evoke Pharma Inc. The current adx is .

Evoke Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Evoke Pharma Inc.

Evoke Pharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Evoke Pharma Inc.

Evoke Pharma Inc Daily Relative Strength Index (RSI) ChartEvoke Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Evoke Pharma Inc.

Evoke Pharma Inc Daily Stochastic Oscillator ChartEvoke Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Evoke Pharma Inc.

Evoke Pharma Inc Daily Commodity Channel Index (CCI) ChartEvoke Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Evoke Pharma Inc.

Evoke Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartEvoke Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Evoke Pharma Inc.

Evoke Pharma Inc Daily Williams %R ChartEvoke Pharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Evoke Pharma Inc.

Evoke Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Evoke Pharma Inc.

Evoke Pharma Inc Daily Average True Range (ATR) ChartEvoke Pharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Evoke Pharma Inc.

Evoke Pharma Inc Daily On-Balance Volume (OBV) ChartEvoke Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Evoke Pharma Inc.

Evoke Pharma Inc Daily Money Flow Index (MFI) ChartEvoke Pharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Evoke Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-01MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Evoke Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Evoke Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.498
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Evoke Pharma Inc with someone you think should read this too:
  • Are you bullish or bearish on Evoke Pharma Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Evoke Pharma Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Evoke Pharma Inc

I send you an email if I find something interesting about Evoke Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Evoke Pharma Inc.

Receive notifications about Evoke Pharma Inc in your mailbox!